Treatment of Patients with Monoclonal Gammopathy of Clinical Significance

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Oct 23

PMID 34680279

Citations 8

Authors

David F Moreno

Laura Rosinol

Maria Teresa Cibeira

Joan Blade

Carlos Fernandez de Larrea

Affiliations

Soon will be listed here.

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is defined as the presence of a monoclonal protein (M-protein) produced by a small amount of plasma cells. The majority of patients remain asymptomatic; however, a fraction of them develop clinical manifestations related to the monoclonal gammopathy despite not fulfilling criteria of multiple myeloma or other lymphoproliferative disorder. These patients constitute an emerging clinical issue coined as monoclonal gammopathy of clinical significance (MGCS). The mechanisms involved are poorly understood, and literature is scarce regarding management. The clinical spectrum involves symptoms related to renal, neurologic, skin, ocular, or bleeding manifestations, requiring a multidisciplinary approach. Treatment strategies rely on the basis of symptomatic disease and the M-protein isotype. In this review, we focus on MGCS other than renal, as the latter was earliest recognized and better known. We review the literature and discuss management from diagnosis to treatment based on illustrative cases from daily practice.

Citing Articles

Neurological manifestations of MGUS.

Cibeira M, Rodriguez-Lobato L, Alejaldre A, Fernandez de Larrea C Hematology Am Soc Hematol Educ Program. 2024; 2024(1):499-504.

PMID: 39644073 PMC: 11665721. DOI: 10.1182/hematology.2024000665.

A rare case of acquired von Willebrand syndrome type 2B: diagnosis, treatment, and underlying pathophysiology.

Jaouen S, Mingant F, Pan-Petesch B, Lippert E, Jeanpierre E, Galinat H Res Pract Thromb Haemost. 2024; 8(5):102516.

PMID: 39228434 PMC: 11369413. DOI: 10.1016/j.rpth.2024.102516.

Pseudohyponatremia: A Concise Guide to Diagnosis and Management in Clinical Practice.

Ballard M, Chen L J Nurse Pract. 2024; 19(10).

PMID: 38854407 PMC: 11154887. DOI: 10.1016/j.nurpra.2023.104800.

Monoclonal gammopathy of clinical significance in a young patient treated with melphalan-thalidomide-prednisone.

Rakotonirainy O, Rakotonirina L, Desana S, Manahandray L, Radinasoa R, Randriamampianina T Clin Case Rep. 2024; 12(6):e8897.

PMID: 38813450 PMC: 11133390. DOI: 10.1002/ccr3.8897.

Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus Dexamethasone.

Kikuchi R, Onozawa M, Nagai J, Okada S, Hasegawa Y, Ohigashi H Intern Med. 2023; 63(4):541-545.

PMID: 37316269 PMC: 10937136. DOI: 10.2169/internalmedicine.2053-23.

References

Colchester N, Allen D, Katifi H, Burt T, Lown R, Pinto A . Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes. Haematologica. 2020; 106(1):302-305. PMC: 7776249. DOI: 10.3324/haematol.2019.243139. View

Castillo J, Advani R, Branagan A, Buske C, Dimopoulos M, DSa S . Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020; 7(11):e827-e837. DOI: 10.1016/S2352-3026(20)30224-6. View

Jain T, Offord C, Kyle R, Dingli D . Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica. 2013; 98(10):1581-5. PMC: 3789463. DOI: 10.3324/haematol.2013.084830. View

Hu Q, Reymond J, Pinel N, Zabot M, Urban Z . Inflammatory destruction of elastic fibers in acquired cutis laxa is associated with missense alleles in the elastin and fibulin-5 genes. J Invest Dermatol. 2005; 126(2):283-90. DOI: 10.1038/sj.jid.5700047. View

Rognvaldsson S, Steingrimsson V, Turesson I, Bjorkholm M, Landgren O, Kristinsson S . Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls. Haematologica. 2020; 105(11):2679-2681. PMC: 7604635. DOI: 10.3324/haematol.2019.239632. View

Djunic I, Elezovic I, Vucic M, Srdic-Rajic T, Konic-Ristic A, Ilic V . Specific binding of paraprotein to platelet receptors as a cause of platelet dysfunction in monoclonal gammopathies. Acta Haematol. 2013; 130(2):101-7. DOI: 10.1159/000345418. View

Garibaldi D, Gottsch J, De La Cruz Z, Haas M, Green W . Immunotactoid keratopathy: a clinicopathologic case report and a review of reports of corneal involvement in systemic paraproteinemias. Surv Ophthalmol. 2004; 50(1):61-80. DOI: 10.1016/j.survophthal.2004.10.002. View

Leger J, Viala K, Nicolas G, Creange A, Vallat J, Pouget J . Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013; 80(24):2217-25. PMC: 3721095. DOI: 10.1212/WNL.0b013e318296e92b. View

Kanagal-Shamanna R, Xu-Monette Z, Miranda R, Dogan A, Zou D, Luthra R . Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2015; 68(4):482-91. PMC: 4704983. DOI: 10.1111/his.12768. View

10.

Dicke C, Schneppenheim S, Holstein K, Spath B, Bokemeyer C, Dittmer R . Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias. Ann Hematol. 2016; 95(6):945-57. DOI: 10.1007/s00277-016-2650-x. View

11.

Ashchyan H, Butler D, Nelson C, Noe M, Tsiaras W, Lockwood S . The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. JAMA Dermatol. 2018; 154(4):409-413. PMC: 5876860. DOI: 10.1001/jamadermatol.2017.5978. View

12.

Tai Y, Mayes P, Acharya C, Zhong M, Cea M, Cagnetta A . Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-38. PMC: 4023420. DOI: 10.1182/blood-2013-10-535088. View

13.

de Koning H . Schnitzler's syndrome: lessons from 281 cases. Clin Transl Allergy. 2015; 4:41. PMC: 4405827. DOI: 10.1186/2045-7022-4-41. View

14.

Kyle R, Therneau T, Rajkumar S, Larson D, Plevak M, Offord J . Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354(13):1362-9. DOI: 10.1056/NEJMoa054494. View

15.

Djunic I, Elezovic I, Ilic V, Milosevic-Jovcic N, Bila J, Suvajdzic-Vukovic N . The effect of paraprotein on platelet aggregation. J Clin Lab Anal. 2014; 28(2):141-6. PMC: 6807480. DOI: 10.1002/jcla.21658. View

16.

Lunn M, Nobile-Orazio E . Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016; 10:CD002827. PMC: 6457998. DOI: 10.1002/14651858.CD002827.pub4. View

17.

Treon S, Tripsas C, Meid K, Warren D, Varma G, Green R . Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015; 372(15):1430-40. DOI: 10.1056/NEJMoa1501548. View

18.

Neel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C . Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. Autoimmun Rev. 2014; 13(10):1035-41. DOI: 10.1016/j.autrev.2014.08.031. View

19.

Owen R, Treon S, Al-Katib A, Fonseca R, Greipp P, McMaster M . Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003; 30(2):110-5. DOI: 10.1053/sonc.2003.50082. View

20.

Moreno D, Pereira A, Tovar N, Cibeira M, Magnano L, Rozman M . Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy. Cancers (Basel). 2021; 13(9). PMC: 8122982. DOI: 10.3390/cancers13092055. View